Company Overview
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +25.85% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +13.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)59.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PBLS Parabilis Medicines, Inc. PHARMA | 39.77 | -21.15 | $4.85B | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 40.24M | 47.45M |
| Operating Income | -40.24M | -47.45M |
| EBITDA | -37.27M | -44.42M |
| Interest Expense | 399.00K | 292.00K |
| Pretax Income | -38.33M | -45.32M |
| Tax Provision | - | - |
| Net Income | -38.33M | -45.32M |
| Diluted EPS | -0.60 | -0.56 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 126.12M | 152.08M |
| Operating Income | -126.12M | -152.08M |
| EBITDA | -114.33M | -141.87M |
| Interest Expense | 1.49M | 1.52M |
| Pretax Income | -117.91M | -145.89M |
| Tax Provision | - | - |
| Net Income | -117.91M | -145.89M |
| Diluted EPS | -2.01 | -1.81 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 149.25M | 80.82M |
| Current Assets | 92.21M | 29.36M |
| Cash & Equivalents | 47.28M | 27.71M |
| Inventory | - | - |
| Receivables | 360.00K | 0 |
| Total Liabilities | 92.81M | 97.34M |
| Current Liabilities | 32.41M | 56.79M |
| Long Term Debt | 12.79M | - |
| Total Debt | 66.20M | 58.70M |
| Total Equity | 56.44M | -16.52M |
| Shares Outstanding | 118.15M | 118.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -103.61M | -123.71M |
| Investing Cash Flow | 30.24M | 39.76M |
| Financing Cash Flow | 78.07M | 64.38M |
| Capital Expenditure | -879.00K | -306.00K |
| Free Cash Flow | -104.49M | -124.02M |
| Net Change in Cash | 4.70M | -19.57M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -208.9% | 882.9% |
| ROCE % | -107.9% | -632.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 23.73% | 28.93M | $1.21B |
| 2 | FMR, LLC | 8.44% | 10.29M | $429.52M |
| 3 | Arch Venture Management, Llc | 5.26% | 6.41M | $267.61M |
| 4 | venBio Partners LLC | 4.32% | 5.27M | $219.78M |
| 5 | Alphabet Inc. | 4.03% | 4.92M | $205.29M |
| 6 | Nextech Invest, Ltd. | 3.82% | 4.66M | $194.59M |
| 7 | Cormorant Asset Management, LP | 3.78% | 4.62M | $192.61M |
| 8 | Regeneron Pharmaceuticals Inc | 3.42% | 4.17M | $173.87M |
| 9 | Siren, L.L.C. | 2.45% | 2.99M | $124.87M |
| 10 | Farallon Capital Management LLC | 1.94% | 2.37M | $98.82M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PBLS
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE4xVVY3TFI3WF93SFNCTWU4YXRYa18zdkxxbWZIQlV6ZTVXNWItX0pBZzlVc2dTWHg2LTZBYzJISjktMjBxRlNYelY4Tkg4S1c3?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P. - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNNk5KZVVNRVJDR3FiRk42ZzRuemhRNDlsRFBOcDZTbE95dk0zVEttMjJDZDU5WkZ4VXNWdjVDbEhCbWJsQUY5S2pDQ3F2cUExYjlENDJfVm9Xa1V6VzdEYzY5T3dEbzVwUHBDUTJLX1N0cmFQelh4bk04TTNjNnkyaURpN29fLTJ5Z3p6Vm…
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQbU5qelItRGhjZkFHS29pMG9VMzA4WVBDNjZtaExhTXhiWU8yOWpuWEI5VzBWS2hmY2UzMTNQekJQOFVXR2NCZzBrTWpKaWFQLU1oaWJJc3dyanlMcFNMZi1TNE9IbndDMXViRmxJVDJJdjBKVk9rLWxYTDB6YjFwT1pOUzQ1TWdJcFFlbG…
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE90dk10VFk2cGpIcjlYem5pU0h2YXY5WnVva1FKYUlsMDF4RVNFSXBCQm5hcnRGNHJKeVR6WGF6QVhkbURyNk5faHJ0a3Z4cmFmWEI0dlR3?oc=5" target="_blank">Parabilis Medicines, Inc. Common Stock (NASDAQ: PBL…
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE8tV0p0TWpKQW1tdmd2eFQzTE9fWllHdFVzR2RRUmNRQXR2aDByaDhoOXFmWkNFdm15Mnh2ME9zMWgwcVZaTEdZ?oc=5" target="_blank">PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart …
Insider Stock Purchases: June 29, 2026 | PBLS Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOYzVmX0h1OEhfQ1hmSC1ncThJMm1WSzE1alJQRDV3cmhsNDh4aHFHeDJjUEd3WjVid05qeW5sYVdrWmhEb2RoOTdtNVA4bktxb0ZmOHpPS08xR201ek80Z214Rmdhbk4zOWtnbGdGcTJTbUdhLTBMeGhjcF9iMTd4Xw?oc=5" target="_…
PBLS — Frequently Asked Questions
What is the current share price of Parabilis Medicines, Inc. (PBLS)?
As of 2026-09-19 21:16 PDT, Parabilis Medicines, Inc. (PBLS) trades at $39.77 on NasdaqGS. Its 52-week range is $25.01 to $41.32.
What is the market capitalisation of PBLS?
Parabilis Medicines, Inc. (PBLS) has a market capitalisation of $4.85B on NasdaqGS.
What is the P/E ratio of PBLS?
PBLS trades at a trailing price-to-earnings (P/E) ratio of -21.15. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.92.
Is PBLS a good stock to buy?
This page provides a data-driven analysis of Parabilis Medicines, Inc. (PBLS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.